BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35529783)

  • 21. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
    Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
    Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
    BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
    Qiao M; Zhou F; Hou L; Li X; Zhao C; Jiang T; Gao G; Su C; Wu C; Ren S; Zhou C
    Ann Transl Med; 2021 Jan; 9(1):34. PubMed ID: 33553327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study.
    Zhou S; Ren F; Li C; Jiang L; Meng X; Huang Z
    J Neurooncol; 2022 Dec; 160(3):631-642. PubMed ID: 36346496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment.
    Tong J; Mao Y; Yang Z; Xu Q; Zheng Z; Zhang H; Wang J; Zhang S; Rong W; Zheng L
    Cancer Manag Res; 2021; 13():4041-4053. PubMed ID: 34040444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study.
    Liu Y; Wang J; Wu J; Yang Q; Zeng Y; Wu D; Tian C; Hu Y; Gu F; Li C; Zhang K; Liu L
    Technol Cancer Res Treat; 2021; 20():1533033821997819. PubMed ID: 33715525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Li S; Liu Z; Ren Y; Liu J; Lv S; He P; Yang Y; Sun Y; Chang J; Luo D; Cong M
    Front Nutr; 2022; 9():900823. PubMed ID: 35923193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors.
    Swart EM; Noordhof AL; Damhuis RAM; Kunst PWA; De Ruysscher DKM; Hendriks LEL; van Geffen WH; Aarts MJ
    Lung Cancer; 2023 Aug; 182():107290. PubMed ID: 37419045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.
    Zhan Q; Miao F; Huang R; Zhou X; Ge M; Liang X
    J Thorac Dis; 2019 Nov; 11(11):4725-4734. PubMed ID: 31903262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitors with or without Radiotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
    Kim DY; Kim PH; Suh CH; Kim KW; Kim HS
    Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33339421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
    Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
    Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 39. The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review.
    Brahm CG; van Linde ME; Enting RH; Schuur M; Otten RHJ; Heymans MW; Verheul HMW; Walenkamp AME
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32143288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
    Zhang S; Yang L; Yang Y; Xin Y; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.